Learn, Analyse & Invest
only with

+91

Download Orca

To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Cohance Lifesciences Ltd.

Cohance Lifesciences

₹ 0.00

0.00 (0.00)%

NSE

BSE

Healthcare

Small-cap - With a market cap of ₹108.04 Cr.

EX-Date	Purpose
08 06 2021	Final Dividend & Audited Results
13 08 2021	Quarterly Results
06 11 2021	Quarterly Results
08 02 2022	Special Dividend
09 05 2022	Interim Dividend & Audited Results
08 08 2022	Quarterly Results
02 09 2022	Interim Dividend
08 11 2022	Quarterly Results
06 02 2023	Quarterly Results
25 05 2023	Audited Results
08 08 2023	Quarterly Results
09 11 2023	Quarterly Results
05 02 2024	Quarterly Results
12 11 2024	Quarterly Results
12 02 2025	Quarterly Results
28 05 2025	Audited Results
13 08 2025	Quarterly Results
12 11 2025	Quarterly Results
12 02 2026	Quarterly Results

News

03-DEC-2025

Cohance Lifesciences gets nod to make $10 million investment in NJ Bio Inc

The fund when deployed will be used by the said subsidiary to support its growth initiatives including capex

12:10 PM

12-SEP-2025

USFDA completes cGMP audit at Cohance Lifesciences’ Andhra Pradesh facility

The inspection was conducted from September 8, 2025 to September 11, 2025 and concluded with zero Form 483 observations

02:23 PM

14-AUG-2025

USFDA completes GMP inspection at Cohance Lifesciences’ Hyderabad facility

Following the inspection, the Company has received a Form 483 from the USFDA with 06 observations

10:30 AM

12-AUG-2025

Cohance Lifesciences to invest $10 million to expand cGMP bioconjugation capabilities at U.S based subsidiary

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline

05:45 PM

20-JUN-2025

Cohance Lifesciences enters into agreements with Chromo Laboratories India

The said transaction is expected to be completed in Q2 FY26, subject to satisfaction of customary closing conditions under the said agreements

03:00 PM

26-MAY-2025

Cohance Lifesciences receives EIR from USFDA for API Unit-IV in Telangana

The inspection was classified as VAI and indicates the formal closure of the inspection process by the USFDA

09:37 AM

21-DEC-2024

Suven Pharmaceuticals acquires 56% stake in NJ Bio

The acquisition of 56% equity share capital of NJ Bio by the company has been completed on December 20, 2024

06:01 PM

07-DEC-2024

Suven Pharmaceuticals to acquire controlling stake in NJ Bio

This acquisition positions the company as a key player in one of the fastest growing segments of the Pharma CDMO landscape

05:29 PM

23-FEB-2024

USFDA completes inspections at Suven Pharmaceuticals’ API, Formulations facilities

The inspections were conducted from February 12, 2024, to February 23, 2024

05:15 PM

30-SEP-2023

Advent International completes acquisition of Suven Pharmaceuticals

As a majority stakeholder, Advent plans to foster Suven’s capabilities to help it strive towards becoming one of the leading companies in the CDMO space globally

03:56 PM

21-APR-2023

CCI approves acquisition of up to 76.10% of voting share capital of Suven by Berhyanda

The Acquirer is the wholly owned subsidiary of Berhyanda Midco

10:00 AM

26-DEC-2022

Advent to acquire significant stake in Suven Pharmaceuticals from Jasti family

The merger will be evaluated by the board taking into consideration the strategic rationale and accretiveness to Suven’s public shareholders

09:42 AM

04-OCT-2022

Suven Pharmaceuticals’ arm gets EIR from USFDA for pre-approval inspection

The pre- approval inspection was conducted during July 25, 2022 through July 29, 2022

02:45 PM